카리오팜 테라퓨틱스(KPTI)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.77 (-1.12%), 시가총액 $0.20B, 52주 최저~최고 $3.77 ~ $10.09.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult
카리오팜 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
카리오팜 테라퓨틱스의 현재 주가는 $1.77 (-1.12%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
카리오팜 테라퓨틱스의 시가총액은 약 $0.20B입니다.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in